Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;214(1):22-30.
doi: 10.1016/j.ajog.2015.07.022. Epub 2015 Jul 26.

Changing paradigms in the systemic treatment of advanced cervical cancer

Krista S Pfaendler  1 , Krishnansu S Tewari  2
Affiliations
Review

Changing paradigms in the systemic treatment of advanced cervical cancer

Krista S Pfaendler et al. Am J Obstet Gynecol. 2016 Jan.

Abstract

Despite availability of primary and secondary prevention measures, cervical cancer persists as one of the most common cancers among women around the world. Although early-stage disease can be cured with radical and even fertility-sparing surgery, patients with metastatic and recurrent cervical cancer have poor prognosis with historically limited treatment options and incurable disease. Significant advances in cervical cancer treatment have emerged as the result of clinical trials that have sought to determine the best therapy to prolong overall and progression-free survival. Most recently, trials that have involved angiogenesis blockade in addition to standard chemotherapy have demonstrated improved overall and progression-free survival. This review serves to highlight pivotal trials in chemotherapy development for advanced, metastatic, and recurrent cervical cancer that includes the paradigm-shifting work that demonstrates increased overall survival with angiogenesis blockade.

Keywords: antiangiogenesis; bevacizumab; cervical cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement:

Dr. Pfaendler has no conflicts of interest.

Figures

Figure 1
Figure 1. Overall survival in GOG 240 according to chemotherapy regimen
Overall survival among patients assigned to cisplatin-paclitaxel (CP) chemotherapy with or without bevacizumab and those assigned to topotecan-paclitaxel (TP) chemotherapy with or without bevacizumab. (©Massachusetts Medical Society. Reprinted with permission from Tewari KS et al. N Engl J Med 2014;370(8):734–743.)
Figure 2
Figure 2. Changing Paradigms in Advanced, Metastatic and Recurrent Cervical Cancer
OS overall survival, PFS progression free survival, HRQoL health related quality of life, VEGF vascular endothelial growth factor. Shown are the paradigm changes described in the text.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Ervik M, et al. [Accessed 4/8/2015];GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet] 2013 http://globocan.iarc.fr.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015 - PubMed
    1. McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil((R))): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014;74(11):1253–1283. - PubMed
    1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology. 1999;189(1):12–19. - PubMed
    1. zur Hausen H, de Villiers EM. Human papillomaviruses. Annual review of microbiology. 1994;48:427–447. - PubMed

Publication types

MeSH terms